


MSCI USA IMI Genomic Innovation Select 50 Index (USD)

The MSCI USA IMI Genomic Innovation Select 50 Index is based on the MSCI USA IMI Index, its parent index, and includes large, mid and small-cap securities of the U.S equity markets. The Index aims to represent the performance of a set of companies that are expected to derive significant revenues, based on the underlying index methodology criteria, from the development of new products and services in the field of genomic sequencing, synthesis, analysis or instrumentation, enable bio computing, bioinformatics, molecular diagnostics and agricultural biotechnology.

For a complete description of the index methodology, please see [Index methodology - MSCI](#).

CUMULATIVE INDEX PERFORMANCE – NET RETURNS (USD) (NOV 2016 – NOV 2025)



ANNUAL PERFORMANCE (%)

Year	MSCI USA IMI Genomic Innovation Select 50	MSCI USA IMI
2024	-1.39	23.32
2023	0.46	25.64
2022	-31.36	-19.61
2021	2.44	25.62
2020	46.58	20.46
2019	36.48	30.39
2018	-10.32	-5.72
2017	34.08	20.59

INDEX PERFORMANCE – NET RETURNS (%) (NOV 28, 2025)

	1 Mo	3 Mo	1 Yr	YTD	ANNUALIZED				Since Nov 30, 2016	FUNDAMENTALS (NOV 28, 2025)			
					3 Yr	5 Yr	10 Yr			Div Yld (%)	P/E	P/E Fwd	P/BV
MSCI USA IMI Genomic Innovation Select 50	6.53	22.74	15.70	23.46	5.15	-2.41	na	7.87		0.25	-398.96	374.92	5.68
MSCI USA IMI	0.14	5.91	13.25	16.84	19.42	13.82	na	14.28		1.18	28.32	22.49	4.96

INDEX RISK AND RETURN CHARACTERISTICS (NOV 30, 2016 – NOV 28, 2025)

	Beta	Tracking Error (%)	Turnover (%) ¹	ANNUALIZED STD DEV (%) ²			SHARPE RATIO ^{2,3}			Since Nov 30, 2016	MAXIMUM DRAWDOWN	
				3 Yr	5 Yr	10 Yr	3 Yr	5 Yr	10 Yr		(%)	Period YYYY-MM-DD
MSCI USA IMI Genomic Innovation Select 50	1.03	15.39	34.13	20.49	22.11	na	0.11	-0.14	na	0.34	53.02	2021-09-09–2023-10-30
MSCI USA IMI	1.00	0.00	1.61	13.30	15.48	na	1.05	0.72	na	0.77	35.04	2020-02-19–2020-03-23

¹ Last 12 months

² Based on monthly net returns data

³ Based on NY FED Overnight SOFR from Sep 1 2021 & on ICE LIBOR 1M prior that date

MSCI USA IMI Genomic Innovation Select 50 Index (USD)

INDEX CHARACTERISTICS

	MSCI USA IMI Genomic Innovation Select 50	MSCI USA IMI
Number of Constituents	50	2,205
	Weight (%)	
Largest	5.40	6.57
Smallest	0.19	0.00
Average	2.00	0.05
Median	1.24	0.01

TOP 10 CONSTITUENTS

	Index Wt. (%)	Parent Index Wt. (%)
NATERA	5.40	0.05
ILLUMINA	5.10	0.03
INSMED	5.06	0.07
LILLY (ELI) & COMPANY	5.00	1.32
DANAHER CORP	4.89	0.22
AGILENT TECHNOLOGIES	4.80	0.07
ABBOTT LABORATORIES	4.74	0.34
VERTEX PHARMACEUTICALS	4.73	0.17
ALNYLAM PHARMACEUTICALS	4.72	0.09
MEDPACE HOLDINGS	4.26	0.02
Total	48.69	2.38

The MSCI USA IMI Genomic Innovation Select 50 Index was launched on Jan 22, 2021. Data prior to the launch date is back-tested test (i.e. calculations of how the index might have performed over that time period had the index existed). There are frequently material differences between back-tested performance and actual results. Past performance – whether actual or back-tested – is no indication or guarantee of future performance.

ABOUT MSCI

MSCI (NYSE: MSCI Inc.) strengthens global markets by connecting participants across the financial ecosystem with a common language. Our research-based data, analytics and indexes, supported by advanced technology, set standards for global investors and help our clients understand risks and opportunities so they can make better decisions and unlock innovation. We serve asset managers and owners, private-market sponsors and investors, hedge funds, wealth managers, banks, insurers and corporates. To learn more, please visit www.msci.com.

The data, data feeds, databases, reports, text, graphs, charts, images, videos, recordings, models, metrics, analytics, indexes, assessments, ratings, scores, software, websites, products, services and other information delivered in connection with this notice (the "Information"): (a) are proprietary information of MSCI and its suppliers, (b) may not be used for commercial purposes without prior written permission from MSCI Inc. or its affiliates ("MSCI"), and (c) are not investment advice and must not be relied on as such. The Information and its use are further subject to the disclaimer at <https://www.msci.com/legal/notice-and-disclaimer>. As detailed therein, MSCI AND ITS SUPPLIERS MAKE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OTHERWISE WITH RESPECT TO THE INFORMATION HEREIN AND DISCLAIM ALL LIABILITY TO THE MAXIMUM EXTENT PERMITTED BY LAW. For information about how MSCI collects and uses personal data, refer to <https://www.msci.com/privacy-pledge>.

© 2025 MSCI Inc. All rights reserved.

